Resveratrol inhibits epithelial-mesenchymal transition in hepatocellular carcinoma | ||
| Journal of Advanced Biomedical and Pharmaceutical Sciences | ||
| Article 4, Volume 7, Issue 1, January 2024, Pages 37-40 PDF (371.1 K) | ||
| Document Type: Review Articles | ||
| DOI: 10.21608/jabps.2023.233421.1201 | ||
| Authors | ||
| Asmaa Bayoumi1; Esraa Khalifa* 2; Mohamed M. Sayed-Ahmed3; Marwa Sharaky3; Maiiada H. Nazmy4 | ||
| 1Department of Biochemistry, Faculty of Pharmacy, Minia University, Minia 61519, Egypt. | ||
| 2Department of Biochemistry, Faculty of Pharmacy, Minia University, Minia 61519, Egypt | ||
| 3Pharmacology and Experimental Oncology Unit, National Cancer Institute, Cairo University, Cairo 11796, Egypt. | ||
| 4Department of Biochemistry, Faculty of Pharmacy, Minia University, Minia 61519, Egypt. | ||
| Abstract | ||
| Hepatocellular carcinoma (HCC) is a brutally aggressive cancer that puts a tremendous amount of strain on both the medical systems and the drug regulatory organizations as well. It is believed that a crucial stage in the development of HCC is the epithelial-mesenchymal transition (EMT), which increases hepatocyte malignancy and is linked to invasion and metastasis. Resveratrol (RES) has been shown to reverse EMT in a number of cancer types. In order to further understand how RES influences EMT in HCC, we have chosen to concentrate on studying and summarizing the serine/threonine kinase (Akt)/glycogen synthesis kinase 3-beta (GSK3β)/Snail signaling pathway as one of the central pathways involved in activating EMT and tumorigenesis in this review. | ||
| Keywords | ||
| Hepatocellular carcinoma; epithelial-mesenchymal transition; resveratrol; Akt/GSK3β/Snail pathway | ||
|
Statistics Article View: 196 PDF Download: 357 |
||
